Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 3
1967 6
1968 3
1969 3
1970 3
1971 6
1974 1
1977 2
1979 2
1980 1
1981 1
1982 2
1983 4
1984 4
1985 3
1986 3
1987 12
1988 7
1989 9
1990 13
1991 4
1992 2
1993 3
1994 7
1995 3
1996 4
1997 6
1998 4
1999 1
2000 4
2001 7
2002 5
2003 3
2004 5
2005 6
2006 10
2007 13
2008 7
2009 5
2010 9
2011 11
2012 11
2013 10
2014 15
2015 20
2016 10
2017 7
2018 7
2019 9
2020 12
2021 9
2022 8
2023 6
2024 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

297 results

Results by year

Filters applied: . Clear all
Page 1
Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. N Engl J Med. 2020. PMID: 32970396 Free article. Clinical Trial.
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Kidney Int. 2022 Jan;101(1):174-184. doi: 10.1016/j.kint.2021.09.005. Epub 2021 Sep 22. Kidney Int. 2022. PMID: 34560136 Free article. Clinical Trial.
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Heerspink HJL, Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJV, Rossing P, Correa-Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Eur Heart J. 2021 Mar 31;42(13):1216-1227. doi: 10.1093/eurheartj/ehab094. Eur Heart J. 2021. PMID: 33792669 Free PMC article. Clinical Trial.
Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial.
Sugawara M, Kojima S, Hisatome I, Matsui K, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Tsujita K, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy (FREED) investigators. Sugawara M, et al. Among authors: waki m. Clin Pharmacol Ther. 2024 Jun;115(6):1358-1364. doi: 10.1002/cpt.3217. Epub 2024 Feb 23. Clin Pharmacol Ther. 2024. PMID: 38389505 Clinical Trial.
[Adrenal hemorrhage].
Waki M. Waki M. Nihon Rinsho. 2006 May 28;Suppl 1:566-9. Nihon Rinsho. 2006. PMID: 16776217 Review. Japanese. No abstract available.
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kohagura K, et al. Among authors: waki m. Hypertens Res. 2023 Jun;46(6):1417-1422. doi: 10.1038/s41440-023-01198-x. Epub 2023 Feb 7. Hypertens Res. 2023. PMID: 36750608 Clinical Trial.
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H. Kojima S, et al. Among authors: waki m. Eur Heart J. 2019 Jun 7;40(22):1778-1786. doi: 10.1093/eurheartj/ehz119. Eur Heart J. 2019. PMID: 30844048 Free PMC article. Clinical Trial.
Development of imaging mass spectrometry.
Saito Y, Waki M, Hameed S, Hayasaka T, Setou M. Saito Y, et al. Among authors: waki m. Biol Pharm Bull. 2012;35(9):1417-24. doi: 10.1248/bpb.b212007. Biol Pharm Bull. 2012. PMID: 22975490 Free article. Review.
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Konishi M, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Konishi M, et al. Among authors: waki m. Int J Cardiol. 2022 Feb 15;349:127-133. doi: 10.1016/j.ijcard.2021.11.076. Epub 2021 Dec 3. Int J Cardiol. 2022. PMID: 34864084 Clinical Trial.
297 results